AFJOG

One step ahead of uterine atony NAME AND BUSINESS ADDRESS OF THE HOLDER OF THE CERTIFICATE OF REGISTRATION: FERRING (Pty.) Ltd. Route 21 Corporate Park, 6 Regency Drive, Irene Ext 30. Pretoria, South Africa. Tel: +27 12 345 6358 www.ferring.co.za. PABAL, PROPESS, TRACTOCILE, FERRING, and the FERRING logo are registered trademarks of Ferring B.V. For full prescribing information please refer to the package insert approved by the medicines regulatory authority. For medical enquiries or to report any adverse events, please send an email to safety.mailbox3@ferring.com . https://bit.ly/3hUP4km. ZA-RMMH-2300024 Effective date: December 2023. PABAL ® (solution for injection). Contains carbetocin (anhydrous acetic acid free): 100 micrograms/ml. Reg. No: A42/19/0383. PROPESS ® 10 mg Vaginal delivery system. Each vaginal delivery system consists of a non-biodegradable polymeric drug delivery device containing 10 mg dinoprostone (prostaglandin E 2 ) dispersed throughout its matrix and releases approximately 0.3 mg/hour prostaglandin E 2 (PGE 2 ) over a 24 hour period. Reg. No. A33/19/0059. TRACTOCILE ® (0,9 ml) 7,5 mg/ml solution for injection (atosiban 7,5 mg/ml). Reg. No. 36/18.9/0335. TRACTOCILE ® (5 ml) 7,5 mg/ml concentrate for solution for infusion (atosiban 7,5 mg/ml). Reg. No. 36/18.9/0336. Our mission at Ferring is to support a woman’s journey to motherhood. Our product portfolio includes Tractocile ® , which helps delay the onset of pre-term birth1, Propess ® , which supports cervical ripening 2 , and Pabal ® , designed to prevent uterine atony. 3 References: 1. Tractocile ® registered package insert, dated 25 September 2022. 2. PROPESS ® Registered Package Insert, dated October 2021. 3. Pabal ® Registered Package Insert, dated 09 June 2022.